Wednesday, November 08, 2017 8:28:53 PM
FDA Commissioner Scott Gottlieb, M.D., has hit back at plans that could see the Pentagon take control over the approval of some experimental drugs and devices for soldiers.
https://www.fiercebiotech.com/biotech/gottlieb-don-t-take-away-fda-s-drug-device-approval-remit-for-soldiers
"Some have criticized the plans for undermining the FDA. This issue has centered on the FDA’s rejection of freeze-dried plasma, something the Pentagon says is necessary to save the lives of military personnel.
“FDA has been working closely with DOD to bring freeze-dried plasma to our troops and anticipates that these products will be fully approved for safe and effective use for our armed forces as early as 2018,” an agency official told Politico this week."
This was from Cytosorbent's presentation at the MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM:
HemoDefend™: Fresh Whole Blood and Universal Plasma Transfusion: Fresh whole blood (FWB) is considered by most military healthcare experts to be superior to blood component transfusions, such as packed red blood cells, in terms of its ability to restore blood volume and to stop bleeding in trauma. An additional advantage of FWB is that it can be directly given by a “walking donor” to the victim at the site of the accident, without the normal logistics and supply chain issues of refrigerated blood. Freeze-dried plasma is another important tool used to resuscitate trauma victims that can be easily carried without the need to refrigerate it. However, the presence of anti-A and anti-B blood group antibodies in both FWB and plasma can lead to dangerous transfusion reactions, therefore requiring very stringent blood-type and antibody level testing. The company highlighted data from the development of new sorbents under the HemoDefend™ brand that are capable of reducing these antibodies from both fresh whole blood and plasma in an ongoing R&D program.
Looks like this may push the FDA to take a look at the HemoDefend solution as a way to get this in place for military use.
Recent CTSO News
- CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification • GlobeNewswire Inc. • 11/04/2024 12:00:00 PM
- FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- CytoSorbents to Report Third Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 10/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 09:25:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 09:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:06:10 PM
- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update • GlobeNewswire Inc. • 10/01/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/01/2024 04:15:18 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/26/2024 09:05:05 PM
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • Nov 7, 2024 8:48 AM
FEATURED SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • Nov 7, 2024 7:00 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM